CoreWeave's $31-$35B Capex Plan: Demand Validation Meets Financing Strain

What happened

CoreWeave guided $31-$35 billion in 2026 capex, confirming surging AI demand and a massive backlog but also intensifying balance-sheet risk. The aggressive spend nearly triples prior-year levels, funded by secured debt that now includes a 1.35x DSCR covenant starting after September 2026. While the $98.8B backlog provides revenue visibility, actual conversion depends on timely data-center go-lives, which face construction, permitting, and equipment bottlenecks. Interest expense is already consuming most operating income, leaving little room for execution slippage or pricing softness. The market now must weigh strong demand signals against the risk that delivery delays or financing constraints could trigger covenant issues or dilution.

Implication

Investors should monitor Q2 2026 revenue against the $2.45-$2.60B guide and adjusted operating income of $30-$90M as a key test of the capex plan's viability. While the $31-$35B spend signals strong customer demand and reinforces the fully sold-out narrative, it locks in a heavy fixed-cost base that magnifies the impact of any delivery delays. The 1.35x DSCR test that begins after September 30, 2026 becomes the critical gating item; if operating cash flow does not scale with interest, creditors could impose tighter terms or force asset sales. Insider selling in May 2026 further underscores risk, suggesting management may be diversifying ahead of potential volatility. A WAIT rating remains appropriate, with an attractive entry near $85; only add after seeing consistent delivery and interest expense below $700M quarterly.

Thesis delta

The $31-$35B capex guidance raises the execution bar and amplifies balance-sheet risk, making timely capacity delivery and stable financing terms even more critical. Previously, the thesis centered on backlog conversion; now, the sheer scale of investment increases the probability that any slippage triggers covenant constraints or dilution. This does not change the WAIT rating but heightens the need for demonstrable operational progress in the next two quarters before considering entry.